Balance Sheet

Accounts Payables Accumulated Depreciation Accumulated Expenses Assets Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Others

Avalo Therapeutics (AVTX) Preferred Stock Liabilities (2024)

Avalo Therapeutics' Preferred Stock Liabilities history spans 3 years, with the latest figure at $1.7 million for Q3 2024.

For Q3 2024, Preferred Stock Liabilities changed N/A year-over-year to $1.7 million; the TTM value through Sep 2024 reached $1.7 million, changed N/A, while the annual FY2014 figure was $28.3 million, N/A changed from the prior year.
Preferred Stock Liabilities reached $1.7 million in Q3 2024 per AVTX's latest filing, down from $11.5 million in the prior quarter.
In the past five years, Preferred Stock Liabilities ranged from a high of $11.5 million in Q1 2024 to a low of $1.7 million in Q3 2024.